Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of VRT106 for Injection in Patients With Recurrent/Progressive Glioblastoma

NCT07093814 is registered in ClinicalTrials.gov with Guangzhou Virotech Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT07093814
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07093814 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of VRT106 for Injection in Patients With Recurrent/Progressive Glioblastoma
Lead sponsor
Guangzhou Virotech Pharmaceutical Co., Ltd.
Phase
Phase 1/2
Overall status
Recruiting
Start date
September 2, 2025
Completion date
June 30, 2029
Enrollment
42 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma